嵌合抗原受体 T 细胞疗法遇到克隆性造血。
CAR T-cell Therapy Meets Clonal Hematopoiesis.
机构信息
Center for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Blood Cancer Discov. 2022 Sep 6;3(5):382-384. doi: 10.1158/2643-3230.BCD-22-0067.
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al., p. 385 (8).
摘要
不定潜能克隆性造血（CHIP）在血液系统恶性肿瘤患者中较为常见。近期文献报道称，CHIP 可能会影响嵌合抗原受体 T 细胞治疗的疗效，且治疗相关毒性（如细胞因子释放综合征和免疫效应细胞相关神经毒性综合征）的发生率可能受到影响。参见 Saini 等人的相关文章，第 385 页（8）。
相似文献
1
CAR T-cell Therapy Meets Clonal Hematopoiesis.嵌合抗原受体 T 细胞疗法遇到克隆性造血。
Blood Cancer Discov. 2022 Sep 6;3(5):382-384. doi: 10.1158/2643-3230.BCD-22-0067.
2
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.克隆性造血与 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤时严重神经毒性风险增加相关。
Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177.
3
Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.嵌合抗原受体 T 细胞（CAR-T）治疗后细胞因子释放综合征和神经毒性的评估和管理。
Expert Opin Biol Ther. 2020 Jun;20(6):653-664. doi: 10.1080/14712598.2020.1729735. Epub 2020 Feb 24.
4
Toxicities of CD19 CAR-T cell immunotherapy.CD19 CAR-T 细胞免疫疗法的毒性。
Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6.
5
Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.细胞因子释放综合征和神经毒性的新见解：CD19 特异性嵌合抗原受体 T 细胞治疗后。
Curr Res Transl Med. 2018 May;66(2):50-52. doi: 10.1016/j.retram.2018.03.003. Epub 2018 Apr 3.
6
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.CD19 导向嵌合抗原受体 T 细胞治疗前桥接治疗对大 B 细胞淋巴瘤患者的影响。
Br J Haematol. 2021 Nov;195(3):405-412. doi: 10.1111/bjh.17738. Epub 2021 Sep 9.
7
Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.一名患有难治性弥漫性大B细胞淋巴瘤且存在克隆性造血的患者在接受抗CD19嵌合抗原受体T细胞输注后不久发生急性髓系白血病。
Haematologica. 2023 Jan 1;108(1):290-294. doi: 10.3324/haematol.2022.281351.
8
Low-Frequency Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma.低频基因突变影响大 B 细胞淋巴瘤中针对 CD19 靶向 CAR T 细胞治疗的反应。
Curr Oncol. 2023 Dec 13;30(12):10463-10476. doi: 10.3390/curroncol30120762.
9
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.嵌合抗原受体 T 细胞疗法相关免疫效应细胞相关神经毒性综合征。
Front Immunol. 2022 Aug 23;13:879608. doi: 10.3389/fimmu.2022.879608. eCollection 2022.
10
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞（CAR-T）疗法在癌症中的风险和益处：系统评价和荟萃分析。
Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14.
引用本文的文献
1
Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia.生物工程免疫活性临床前芯片试验工具可用于筛选白血病的嵌合抗原受体T细胞疗法。
Nat Biomed Eng. 2025 Jul 1. doi: 10.1038/s41551-025-01428-2.
2
The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy.克隆性造血在扩张型心肌病发病机制中的新作用。
Eur Heart J. 2024 Oct 17;45(45):4797-807. doi: 10.1093/eurheartj/ehae682.
3
Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis.嵌合抗原受体 T 细胞疗法与造血。
Cells. 2023 Feb 7;12(4):531. doi: 10.3390/cells12040531.
4
Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.抗 CD19 CAR-T 细胞治疗后突变 TP53 相关克隆性造血的致命进展。
Curr Oncol. 2023 Jan 13;30(1):1146-1150. doi: 10.3390/curroncol30010087.
本文引用的文献
1
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.接受 CAR T19 治疗的 B 细胞 ALL 患者的细胞因子释放综合征和免疫效应细胞相关神经毒性综合征的综合血清蛋白质组谱分析。
Clin Cancer Res. 2022 Sep 1;28(17):3804-3813. doi: 10.1158/1078-0432.CCR-22-0822.
2
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.克隆性造血与 axicabtagene ciloleucel 治疗大 B 细胞淋巴瘤时严重神经毒性风险增加相关。
Blood Cancer Discov. 2022 Sep 6;3(5):385-393. doi: 10.1158/2643-3230.BCD-21-0177.
3
Next-Generation CAR T-cell Therapies.下一代嵌合抗原受体 T 细胞疗法。
Cancer Discov. 2022 Jul 6;12(7):1625-1633. doi: 10.1158/2159-8290.CD-21-1683.
4
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment.接受 CD19 靶向 CAR T 细胞治疗的侵袭性淋巴瘤患者中 CHIP 的流行率和变异情况。
Blood Adv. 2022 Mar 22;6(6):1941-1946. doi: 10.1182/bloodadvances.2021005747.
5
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.删除 CAR T 细胞中的 DNMT3A 可防止衰竭并增强抗肿瘤活性。
Sci Transl Med. 2021 Nov 17;13(620):eabh0272. doi: 10.1126/scitranslmed.abh0272.
6
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗患者的克隆性造血。
Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554.
7
Clonal hematopoiesis and its emerging effects on cellular therapies.克隆性造血及其对细胞治疗的新影响。
Leukemia. 2021 Oct;35(10):2752-2758. doi: 10.1038/s41375-021-01337-8. Epub 2021 Jul 2.
8
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.供者克隆性造血会增加亲缘全相合造血干细胞移植后急性移植物抗宿主病的风险。
Leukemia. 2022 Jan;36(1):257-262. doi: 10.1038/s41375-021-01312-3. Epub 2021 Jun 16.
9
Cytokine Storm.细胞因子风暴
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
10
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.靶向CD19的嵌合抗原受体T细胞免疫疗法的疗效与载体整合导致的基因修饰相关。
J Clin Invest. 2020 Feb 3;130(2):673-685. doi: 10.1172/JCI130144.
Zotero 插件